Navigation Links
Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Date:3/31/2008

hese cases, HPV testing can help determine appropriate medical management. The other arm enrolls women over age 30 whose Pap results are normal. This arm will assess the ability of the APTIMA HPV test to identify women who are at greater risk for cervical cancer.

Gen-Probe expects to enroll approximately 7,000 women in the study. Actual enrollment, however, may vary based on the prevalence of cervical disease among women in the trial. The trial enrollment and testing are expected to take approximately two years.

The APTIMA HPV assay is designed to run on Gen-Probe's fully automated, high-throughput TIGRIS(R) instrument system, and on the Company's current and future medium-throughput instrument platforms.

Separately, Gen-Probe remains on track to introduce its APTIMA HPV assay as a CE-marked product in Europe in the second half of 2008.

About HPV and Cervical Cancer

HPV is a group of viruses with more than 100 types, 14 of which have been categorized as high risk for the development of cervical cancer. While most women will be infected with HPV at some point in their lives, the majority of these infections are transient and resolve without any clinical symptoms or consequences. However, a small number of HPV infections progress and result in disease ranging from genital warts to cervical cancer. Since most HPV infections do not result in cancer, there is a need for a more specific test to identify women at greater risk of developing that disease.

The most common test used for cervical cancer screening in the United States is the Pap test. Since the mid-1950s, screening with the Pap test has dramatically reduced the number of deaths from cervical cancer. Even so, the American Cancer Society estimates that there were more than 11,000 new cases of invasive cervical cancer in 2007, as well as nearly 4,000 deaths from the disease.

Despite the success of Pap testing in reducing mortality from cervical cancer in the United S
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MEXICO CITY , July 25, 2014 IBM ... Latin American healthcare sciences publisher, launched a library of ... conditions such as cancer and heart disease. Healthcare providers ... up-to-date information to deliver better patient care. ... with many relying on smartphones and tablets to access ...
(Date:7/25/2014)... BERWYN, Pa. , July 25, 2014  AMETEK, ... appointment of Kurtis L. Goos as Vice ... Engineered Materials, Interconnects and Packaging (EMIP) Division. ... has extensive general management and business development experience, especially ... to make important contributions to the continued growth and ...
(Date:7/25/2014)... July 25, 2014 NOT FOR RELEASE, ... INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO ... REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ) ... 30, 2014. "This was another very strong ... share above our original guidance and announced plans to merge ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European ... market in Europe with analysis and forecast of revenue. ... grow from around $509.4 million in 2013 to $657.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. It also provides ...
(Date:7/27/2014)... The report provides market analysis of ... Analysis (Commercial Aviation And Defense Aviation Landing Gear, ... Forecasts 2014 - 2019." The report covers the ... the market during the study period. It also ... are currently prevailing in the global market. , ...
(Date:7/27/2014)... 27, 2014 Metachromatic leukodystrophy (MLD, ... storage disease which is commonly listed in the ... sphingolipidoses as it affects the metabolism of sphingolipids. ... the fatty covering which acts as an insulator ... nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic ...
(Date:7/27/2014)... Although Cigarette and Tobacco ... two companies, heavy government regulation results in extremely ... Little, “Demand for cigarettes has declined over the ... frequent anti-smoking campaigns, increasing regulation and higher excise ... to fall at a compound annual 0.8% over ...
(Date:7/27/2014)... Dallas, Texas (PRWEB) July 27, 2014 One ... demand for genomics products from the Asia Pacific (APAC) region. ... is expected to generate high demand for genomics solutions, thereby ... Genomics market will grow at a CAGR of 11.21 ... most important driver of the market is an increase in ...
Breaking Medicine News(10 mins):Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Cigarette and Tobacco Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 2Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 3Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 4Health News:Genomics, Single Nucleotide Polymorphism Genotyping and Analysis Market 2014 – 2018 in New Research Report at Sandlerresearch.org 5
... 15 Darwin,Professional Underwriters, Inc. (the "Company") (NYSE: ... meeting of the Company,s stockholders held on October ... Plan of Merger,(the "Merger Agreement"), dated as of ... Company Holdings, Ltd ("Allied World") and Allied,World Merger ...
... 15 /PRNewswire/ - A popular drug used to ... attacks does not improve,outcomes for patients undergoing a ... as eptifibatide (pronounced ep-ti-fy-bah-tide),- also increases the risk ... conducted at the University of Ottawa Heart Institute ...
... researchers, including scientists from the University of Florida, has ... neuroblastoma, a type of cancer responsible for 15 percent ... human cell lines and tissue samples, researchers describe in ... how they were able to short-circuit genetic processes ...
... Oct. 15 Post-graduate education has,never been more ... according to recent studies and reports published by ... class of 2008, almost 40 percent of graduating ... education -- 89.2 percent of,those into internships and ...
... Oct. 15 CTG HealthCare Solutions,(CTGHS), a leading ... unit of CTG (Nasdaq: CTGX ), an ... it was awarded a series of,engagements in support ... providing services to a major children,s hospital with ...
... Oct. 15 Thomson Reuters, the,world,s leading source ... the launch of Thomson Pharma KOLexperts, a,new solution ... productive relationships with key opinion leaders,(KOLs) and scientific ... the,industry that allows users to rank life sciences ...
Cached Medicine News:Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 2Health News:Darwin Stockholders Adopt Merger Agreement with Allied World 3Health News:University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding 2Health News:Scientists close in on method to fight deadly childhood cancer 2Health News:Scientists close in on method to fight deadly childhood cancer 3Health News:Post-Graduate Veterinary Education - Residencies and Internships - Becoming Very Popular Among New Veterinarians 2Health News:CTG HealthCare Solutions Announces New EPIC Implementation Engagements 2Health News:CTG HealthCare Solutions Announces New EPIC Implementation Engagements 3Health News:Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders 2
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... CT/GC Controls are liquid controls ... of test procedures that detect ... Since they are specimen specific, ... either urine or endocervical/urethral swabs ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: